Bayesian Capital Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bayesian Capital Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7,638	Closed	-$213K	–	739
2023 Q3	$213K	Buy	+7,638	New	+$250K	0.02%	538
2022 Q4	–	Sell	-15,378	Closed	-$505K	–	773
2022 Q3	$505K	Sell	15,378 -600	-4%	-$22K	0.1%	282
2022 Q2	$503K	Buy	+15,978	New	+$559K	0.09%	335
2022 Q1	–	Sell	-8,300	Closed	-$508K	–	769
2021 Q4	$508K	Sell	8,300 -400	-5%	-$27.7K	0.16%	169
2021 Q3	$650K	Buy	+8,700	New	+$730K	0.19%	144

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MMEA

Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Main Management San Francisco, California $1.37B AUM 19.06% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bayesian Capital Management's ARKG Position: Q4 2023 in Review

Bayesian Capital Management sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2023, closing a stake of 7,638 shares — an estimated $213K sold.

Bayesian Capital Management first reported a position in ARKG in Q3 2021 and held it in 5 quarters. The position peaked at $650K in Q3 2021. 298 funds tracked by Wall St. Rank hold ARKG as of Q4 2023.

Bayesian Capital Management reported no remaining ARK Genomic Revolution ETF position as of Q4 2023 after selling out during the quarter.
Bayesian Capital Management sold 7,638 ARK Genomic Revolution ETF shares in Q4 2023, an estimated $213K.
Bayesian Capital Management first reported a position in ARK Genomic Revolution ETF in Q3 2021 and held it in 5 quarters.
Bayesian Capital Management's ARK Genomic Revolution ETF position peaked at $650K in Q3 2021.
298 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2023.

Based on Bayesian Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.